National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892, United States
NCT Number: NCT00001530
DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial effects of pacing are evident in sinus rhythm. The long term results of this novel therapy are, however, uncertain. We propose (1) to record the hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing continues to be necessary in patients who have had a substantial relief of their LVOT obstruction. Patients who have had >50% reduction in LVOT pressure gradients will be randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats per minute (DDD switched off), and reevaluated after a six-month period.
Looking for future studies?
Notify MeAll sexes
Observational
Bethesda, Maryland, 20892, United States
DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial effects of pacing are evident in sinus rhythm. The long term results of this novel therapy are, however, uncertain. We propose (1) to record the hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing continues to be necessary in patients who have had a substantial relief of their LVOT obstruction. Patients who have had >50% reduction in LVOT pressure gradients will be randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats per minute (DDD switched off), and reevaluated after a six-month period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Group 1:
HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at the NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms.
Group 2:
HCM patients selected from Group 1 who at the follow-up cardiac catheterization are demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT obstruction (greater than 50% reduction in LVOT gradient).
Patient who have developed a heart block will be excluded from group 2.
Females must have a negative pregnancy test.
National Heart, Lung, and Blood Institute (NHLBI)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001965
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT00074880
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT05582395
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Birmingham, Alabama, United States
View Trial DetailsNCT04164732
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Stanford, California, United States
View Trial Details